Related references
Note: Only part of the references are listed.Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm
Philip A. Beer et al.
BLOOD (2010)
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
Sylvain Thepot et al.
BLOOD (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
Therapeutic options for patients with myelofibrosis in blast phase
John Mascarenhas et al.
LEUKEMIA RESEARCH (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
A. Quintas-Cardama et al.
LEUKEMIA (2008)
JAK and MPL mutations in myeloid malignancies
Ayalew Tefferi
LEUKEMIA & LYMPHOMA (2008)
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
P. W. Wijermans et al.
LEUKEMIA RESEARCH (2008)
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT 5 pathway activation
Ying Wang et al.
BLOOD (2007)
The JAK-STAT pathway: A therapeutic target in hematological malignancies
A. Ferrajoli et al.
CURRENT CANCER DRUG TARGETS (2006)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Janus kinase 2: A critical target in chronic myelogenous leukemia
Ajoy K. Samanta et al.
CANCER RESEARCH (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia
RT Williams et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
RA Mesa et al.
BLOOD (2005)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
STAT signaling in the pathogenesis and treatment of leukemias
TS Lin et al.
ONCOGENE (2000)
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
J Schwaller et al.
MOLECULAR CELL (2000)
Share Paper
